Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | OXER1 | Q8TDS5 | 8/20 | 0.41 |
| ▸ | NR1H2 | P55055 | 2/20 | 0.39 |
| ▸ | NOD2 | Q9HC29 | 1/20 | 0.39 |
| ▸ | NOD1 | Q9Y239 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.38 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5519418 | 0.84 | NR1H2 (0.56) | NR1H2 | |
| SCHEMBL4792786 | 0.84 | MAPT (0.44) | L3MBTL1NPC1RAB9AOXER1NR1H2 | |
| SCHEMBL17075022 | 0.80 | L3MBTL1 (0.47) | L3MBTL1NR1H2NOD2NOD1POLB | |
| SCHEMBL28615203 | 0.76 | L3MBTL1 (0.47) | L3MBTL1NR1H2NOD2NOD1MTNR1A | |
| SCHEMBL6988070 | 0.75 | MTNR1A (0.51) | L3MBTL1NOD2NOD1MTNR1AMTNR1B | |
| SCHEMBL6988076 | 0.75 | MCL1 (0.58) | L3MBTL1NPC1RAB9ANOD2NOD1 | |
| SCHEMBL6706688 | 0.74 | NOD2 (0.51) | L3MBTL1OXER1NR1H2NOD2NOD1 | |
| SCHEMBL28011916 | 0.73 | NR1H2 (0.54) | NR1H2 | |
| SCHEMBL28455040 | 0.72 | NOD2 (0.47) | L3MBTL1OXER1NR1H2NOD2NOD1 | |
| SCHEMBL27700921 | 0.71 | OXER1 (0.39) | NPC1RAB9AOXER1NR1H2NOD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7229987-B2 | Multicyclic compounds for use as melanin concentrating hormone antagonists in the treatment of obesity and diabetes | ELI LILLY AND COMPANY (US) | 2007-06-12 | — | — | US | disclosed |
| US-20050272718-A1 | Multicyclic compounds for use as melanin concentrating hormone antagonists in the treatment of obesity and diabetes | AMMENN ET AL, JOCHEN | 2005-12-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050272718-A1 | Multicyclic compounds for use as melanin concentrating hormone antagonists in the treatment of obesity and diabetes | MC1R, MC4R, MC5R | L3MBTL1 2576/4885NPC1 457/4885RAB9A 1063/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.